What is Indaptus Therapeutics?
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology firm headquartered in New York City. The company is dedicated to pioneering innovative immunotherapies aimed at treating cancer and infectious diseases. Its core strategy involves harnessing the body's natural immune defenses through the use of engineered, non-pathogenic gram-negative bacteria. This unique approach is designed to stimulate a broad spectrum of immune responses, positioning Indaptus Therapeutics at the forefront of next-generation therapeutic development.
How much funding has Indaptus Therapeutics raised?
Indaptus Therapeutics has raised a total of $2.3M across 1 funding round:
Debt
$2.3M
Debt (2025): $2.3M with participation from Paulson Investment Company
Key Investors in Indaptus Therapeutics
Paulson Investment Company
Paulson Investment Company is a boutique investment banking and broker-dealer firm specializing in capital markets expertise for small and mid-sized companies. They focus on long-term financial advisory services and client relationships, emphasizing integrity and strategic insight to facilitate corporate growth and access to capital markets.
What's next for Indaptus Therapeutics?
The recent major enterprise-level funding signifies a critical growth phase for Indaptus Therapeutics. This capital infusion is expected to accelerate the company's clinical development pipeline, potentially enabling further research and expansion into new therapeutic areas. The strategic investment suggests strong confidence from backers in the company's technology and its potential to address significant unmet medical needs in oncology and infectious disease treatment.
See full Indaptus Therapeutics company page
